| Title |
Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy)
|
|---|---|
| Published in |
Journal for Immunotherapy of Cancer, July 2018
|
| DOI | 10.1186/s40425-018-0377-z |
| Pubmed ID | |
| Authors |
Paolo A. Ascierto, James Brugarolas, Luigi Buonaguro, Lisa H. Butterfield, David Carbone, Bruno Daniele, Robert Ferris, Bernard A. Fox, Jérôme Galon, Cesare Gridelli, Howard L. Kaufman, Christopher A. Klebanoff, Ignacio Melero, Paul Nathan, Chrystal M. Paulos, Marco Ruella, Ryan Sullivan, Hassane Zarour, Igor Puzanov |
| Abstract |
Immunotherapy represents the third important wave in the history of the systemic treatment of cancer after chemotherapy and targeted therapy and is now established as a potent and effective treatment option across several cancer types. The clinical success of anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4, first, and anti-programmed death (PD)-1/PD-ligand (L)1 agents in melanoma and other cancers a few years later, has encouraged increasing focus on the development of other immunotherapies (e.g. monoclonal antibodies with other immune targets, adoptive cell transfer, and vaccines), with over 3000 immuno-oncology trials ongoing, involving hundreds of research institutes across the globe. The potential use of these different immunotherapeutic options in various combinations with one another and with other treatment modalities is an area of particular promise. The third Immunotherapy Bridge meeting (29-30 November, 2017, Naples, Italy) focused on recent advances in immunotherapy across various cancer types and is summarised in this report. |
X Demographics
The data shown below were collected from the profiles of 25 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 9 | 36% |
| Italy | 4 | 16% |
| Japan | 1 | 4% |
| Bulgaria | 1 | 4% |
| Turkey | 1 | 4% |
| India | 1 | 4% |
| Singapore | 1 | 4% |
| Spain | 1 | 4% |
| United Kingdom | 1 | 4% |
| Other | 0 | 0% |
| Unknown | 5 | 20% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 15 | 60% |
| Practitioners (doctors, other healthcare professionals) | 5 | 20% |
| Scientists | 4 | 16% |
| Science communicators (journalists, bloggers, editors) | 1 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 75 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 75 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 13% |
| Student > Ph. D. Student | 8 | 11% |
| Other | 7 | 9% |
| Student > Master | 7 | 9% |
| Student > Bachelor | 6 | 8% |
| Other | 15 | 20% |
| Unknown | 22 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 21% |
| Biochemistry, Genetics and Molecular Biology | 10 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 8% |
| Immunology and Microbiology | 5 | 7% |
| Agricultural and Biological Sciences | 4 | 5% |
| Other | 15 | 20% |
| Unknown | 19 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 August 2018.
All research outputs
#2,318,720
of 25,385,509 outputs
Outputs from Journal for Immunotherapy of Cancer
#627
of 3,422 outputs
Outputs of similar age
#46,117
of 339,438 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#17
of 41 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,422 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.4. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 339,438 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 41 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.